Clinical Trial Update: Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reports efficacy and long-term safety data for vildagliptin as monotherapy in type 2 diabetes across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 2, Phase 3 | Status: COMPLETED